title: Cervical cancer screening in pregnancy.
abstract: Cervical cancer is the most commonly diagnosed malignancy during pregnancy with an incidence of 1.5 to 12 per 100,000 pregnancies. In the United States between 2% and 7% of all pregnant women will have an abnormal Pap test. The management of these abnormal results during pregnancy can present a challenge to the practitioner. This article reviews recently published guidelines and current evidence for evaluation and management of abnormal cervical cytology and cervical cancer in pregnancy.
authors.affiliation: Division of Gynecology, Department of Obstetrics and Gynecology, University of New Mexico, 1 University of New Mexico, Albuquerque, NM 87131-0001, USA. jstonehocker@salud.unm.edu
authors.forename: Jody
authors.initials: J
authors.lastname: Stonehocker
mesh_terms: D001706:Biopsy; D003127:Colposcopy / Q000009:adverse effects / Q000379:methods; D005260:Female; D005865:Gestational Age; D006801:Humans; D008403:Mass Screening / Q000009:adverse effects* / Q000379:methods; D009361:Neoplasm Invasiveness; D065006:Papanicolaou Test / Q000009:adverse effects; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000473:pathology* / Q000601:surgery; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000601:surgery; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000473:pathology* / Q000601:surgery; D014626:Vaginal Smears / Q000009:adverse effects